Physio-metabolic method of treating androgenic alopecia. Cold receptors. The relationship between DHT, cold receptors, minoxidil and antiandrogens.
    12/7/2024

    From the encyclopedia
    Minoxidil →

    Vasodilator used on the scalp and, at low doses, as a tablet

    Dutasteride →

    5-alpha reductase inhibitor that blocks both enzyme types, a stronger DHT blocker than finasteride

    Ketoconazole →

    Antifungal, best known as a dandruff shampoo

    At a glance
    In this educational post, the primary subjects mentioned are
    💊 Minoxidil (oral) 5mg 2x daily
    💊 Dutasteride (oral) 1mg
    • Microneedling 1x weekly
    💧 Tichoxidil (topical) 2.5%
    💧 Minoxidil (topical) 5%
    💧 Menthol ointment (topical) 1x weekly
    the tone is 😐 neutral.

    Other terms

    A method for treating androgenic alopecia using minoxidil, antiandrogens, exercise, and cold exposure to promote hair growth. Environmental factors and lifestyle changes, like diet and exercise, can improve treatment effectiveness.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results

      research The involvement of androgens in human hair growth

      3 citations , April 2015 in “American journal of biomedical sciences”
      This review discusses the molecular mechanisms of androgen action in human hair follicles and reports no new findings; the authors emphasize the need for further research to improve treatments for hair disorders.

      research Hair aging and anti-aging

      3 citations , October 2007 in “Expert Review of Dermatology”
      This review discusses the biological and cosmetic aspects of hair aging and reports no new clinical results; it highlights current treatments and future research directions to address both aging factors.

      research Investigational medications in the treatment of alopecia

      3 citations , February 2005 in “Expert Opinion on Investigational Drugs”
      This review discusses investigational treatments for androgenetic and chemotherapy-induced alopecia and reports no new clinical results, highlighting the need for further research.